

## **Xylanase from *Bacillus licheniformis***

An application to amend the Australia New Zealand Food Standards Code with a xylanase preparation produced by a genetically modified strain of *Bacillus licheniformis*

# Table of Contents

Xylanase from <i>Bacillus licheniformis</i> .....	1
An application to amend the Australia New Zealand Food Standards Code with a xylanase preparation produced by a genetically modified strain of <i>Bacillus licheniformis</i> .....	1
Executive summary .....	4
Introduction .....	6
Chapter 3.1, General requirements for applications.....	7
A Executive summary .....	7
B Applicant details .....	7
C Purpose of the application .....	8
D Justification for the application.....	8
The need for the proposed change.....	8
The advantages of the proposed change over the status quo .....	8
D.1 Regulatory impact information .....	9
E Information to support the application.....	9
E.1 Data requirements .....	9
F Assessment procedure .....	9
G Confidential commercial information (CCI) .....	10
H Other confidential information.....	10
I Exclusive capturable commercial benefit (ECCB) .....	10
J International and other national standards .....	10
J.1 International Standards.....	10
J.2 Other national standards or regulations .....	10
K Statutory declaration.....	10
L Checklist.....	10
Chapter 3.3, Guidelines for applications for substances added to food.....	11
3.3.2 Processing Aids .....	11
A Technical information on the processing aid .....	11
A.1 Information on the type of processing aid.....	11
A.2 Information on the identity of the processing aid .....	11
A.3 Information on the chemical and physical properties of the processing aid .....	13
A.4 Manufacturing process.....	13
A.5 Specification for identity and purity.....	17
A.6 Analytical method for detection .....	18
B Information related to the safety of a chemical processing aid.....	18
C Information related to the safety of an enzyme processing aid .....	18

C.1 General information on the use of the enzyme as a food processing aid in other countries .....	18
C.2 Information on the potential toxicity of the enzyme processing aid .....	18
C.3 Information on the potential allergenicity of the enzyme processing aid .....	19
C.4 Safety assessment reports prepared by international agencies or other national government agencies, if available .....	20
D Additional information related to the safety of an enzyme processing aid derived from a microorganism .....	21
D.1 Information on the source microorganism .....	21
D.2 Information on the pathogenicity and toxicity of the source microorganism .....	21
D.3 Information on the genetic stability of the source organism .....	22
E Additional information related to the safety of an enzyme processing aid derived from a genetically-modified microorganism .....	22
E.1 Information on the methods used in the genetic modification of the source organism .....	22
F Information related to the dietary exposure to the processing aid .....	24
F.1 A list of foods or food groups likely to contain the processing aid or its metabolites .....	24
F.2 The levels of residues of the processing aid or its metabolites for each food or food group .....	24
F.3 For foods or food groups not currently listed in the most recent Australian or New Zealand National Nutrition Surveys (NNSs), information on the likely level of consumption .....	26
F.4 The percentage of the food group in which the processing aid is likely to be found or the percentage of the market likely to use the processing aid .....	26
F.5 Information relating to the levels of residues in foods in other countries .....	26
F.6 For foods where consumption has changed in recent years, information on likely current food consumption .....	27
List of references .....	28
List of appendices .....	30

## Executive summary

The present application seeks to amend Schedule 18—Processing aids of the Australia New Zealand Food Standards Code (the Code) to approve a xylanase enzyme preparation produced by Novozymes.

### Proposed change to Australia New Zealand Food Standards Code – Schedule 18—Processing aids

Schedule 18—Processing aids is proposed to be amended to include a genetically modified strain of *Bacillus licheniformis* expressing a xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium sp-10696*) as permitted source for xylanase.

The application is applied for assessment by the general procedure.

### Description of enzyme preparation

The enzyme is an endo-1,4- $\beta$ -xylanase (EC 3.2.1.8), commonly known as xylanase.

Xylanase catalyses the hydrolysis of (1 $\rightarrow$ 4)- $\beta$ -D-xylosidic linkages in xylans.

The enzyme is produced by submerged fermentation of a *Bacillus licheniformis* microorganism expressing a xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium sp-10696*).

The xylanase enzyme preparation is available as a liquid preparation complying with the JECFA recommended purity specifications for food-grade enzymes.

The producing microorganism, *Bacillus licheniformis*, is absent from the commercial enzyme product.

### Use of the enzyme

The xylanase enzyme preparation is used as a processing aid in distilled alcohol production and the production of starch and gluten fractions. Generally, xylanases hydrolyse xylosidic linkages in xylans, including arabinoxylan present in grains for the production of several products, e.g., gluten, starch, potable alcohol, beer, and fats and oils.

- during beverage alcohol (distilling) processes the xylanase is used in order to degrade gelatinised starch and dextrans into glucose and other fermentable sugars.
- During the production of starch and gluten fractions the xylanase degrades xylans, including arabinoxylans (also called pentosans), into oligosaccharides of variable.

### Benefits

The benefits of the action of the xylanase in distilled alcohol production are:

- Higher solid concentration during mashing (energy efficiency).
- Improved heat exchange.
- Improved centrifugal separation.
- Improved mass transfer in fermentation.
- Increased fermentable sugars from beta glucan hydrolysis.

The benefits of the action of the xylanase in the production of starch and gluten fractions are:

- Higher gluten and starch yield due to efficient targeted degradation of the highly branched arabinoxylans of the cereal/grain fibre.
- More efficient removal of trapped water from the fibre, resulting in reduced evaporation load, leading to energy savings.
- Smoother operations and increased plant capacity.

### **Safety evaluation**

The safety of the production organism and the enzyme product has been thoroughly assessed:

- The production organism has a long history of safe use as production strain for food-grade enzyme preparations and is known not to produce any toxic metabolites.
- The genetic modifications in the production organism are well-characterised and safe and the recombinant DNA is stably integrated into the production organism and unlikely to pose a safety concern.
- The enzyme preparation complies with international specifications ensuring absence of contamination by toxic substances or noxious microorganisms
- Sequence homology assessment to known allergens and toxins shows that oral intake of the xylanase does not pose food allergenic or toxic concern.
- Two mutagenicity studies showed no evidence of genotoxic potential of the enzyme preparation.
- An oral gavage administration study in rats for 13-weeks showed that all dose levels were generally well tolerated and no evidence of toxicity.

Furthermore, the safety of the xylanase preparation was confirmed by external expert groups, as follows:

- Denmark: The enzyme preparation was safety assessed resulting in the authorisation of the enzyme product by the Danish Veterinary and Food Administration.
- France: The enzyme preparation was evaluated and approved by the competent authorities in France (Sous-direction de la sécurité sanitaire des aliments, Bureau des établissements et produits des industries alimentaires spécialisées).

### **Conclusion**

Based on the Novozymes safety evaluation, confirmed by the above-mentioned bodies, we respectfully request the inclusion of the xylanase in Schedule 18—Processing aids.

## Introduction

The present application describes a xylanase enzyme preparation produced by submerged fermentation of a *Bacillus licheniformis* microorganism producing a xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium* sp-10696).

The enzyme is an endo-1,4- $\beta$ -xylanase (EC 3.2.1.8), commonly known as xylanase. The enzyme catalyses the hydrolysis of (1 $\rightarrow$ 4)- $\beta$ -D-xylosidic linkages in xylans.

The xylanase enzyme preparation is intended to be used as a processing aid in the grain-processing industry to hydrolyse xylans, including arabinoxylan present in grains for the production of several products, e.g., gluten, starch, potable alcohol, beer, and fats and oils.

The following sections describe in detail the construction of the genetically modified *Bacillus licheniformis* used as the production organism, the production process, the product specification, the application of the enzyme preparation and finally the safety evaluation of the product including the toxicology program, which has been carried out confirming the safety of the product for its intended use.

The documentation has been elaborated according to the Application Handbook from Food Standards Australia New Zealand as of 1 July 2019, applied as relevant for an enzyme application, *i.e.*, outlining the following section:

- Section 3.1.1 – General requirements
- Section 3.3.2 – Processing aids, subsections A, C, D, E, F

**NB! In Appendix 2.1**, the xylanase enzyme preparation is described by its commercial name, NS 280535 xylanase.

## Chapter 3.1, General requirements for applications

### A Executive summary

An Executive Summary is provided as a separate copy together with this application.

### B Applicant details

(a) **Applicant's name/s**

[REDACTED]

(b) **Company/organisation name**

Novozymes Australia Pty Ltd

(c) **Address (street and postal)**

[REDACTED]

[REDACTED]

(d) **Telephone number**

[REDACTED]

(e) **Email address**

[REDACTED]

(f) **Nature of applicant's business**

Biotechnology

(g) **Details of other individuals, companies or organisations associated with the application**

**Submission prepared by:**

*To whom correspondence should be directed:*

[REDACTED]

[REDACTED]

Novozymes Japan Ltd.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

## C Purpose of the application

This application is submitted to provide for amendment of the Australia New Zealand Food Standards Code, Schedule 18—Processing aids to include a genetically modified strain of *Bacillus licheniformis* as permitted source for a xylanase.

## D Justification for the application

### The need for the proposed change

Schedule 18—Processing aids contains a list of permitted enzymes of microbial origin, among others xylanases (EC 3.2.1.8) from different sources, including *Bacillus licheniformis*. However, Schedule 18—Processing aids does not contain a xylanase (EC 3.2.1.8) from *Bacillus licheniformis* containing the gene for xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium* sp-10696).

*Bacillus licheniformis* is an approved host and production strain for a number of enzymes in Schedule 18—Processing aids, e.g. a wide range of enzymes that can be used in xylan processing such as alpha-amylase, beta-galactosidase, chymotrypsin, endo-1,4-beta-xylanase, maltogenic alpha-amylase, pullulanase, serine proteinase.

### The advantages of the proposed change over the status quo

The xylanase preparation is used as a processing aid during the manufacture of xylan-based products. Xylanases hydrolyse xylosidic linkages in xylans, including arabinoxylan present in grains for the production of several products, e.g. gluten, starch, potable alcohol, beer, and fats and oils.

The benefits of the action of the xylanase in distilled alcohol production are:

- Higher solid concentration during mashing (energy efficiency).
- Improved heat exchange.
- Improved centrifugal separation.
- Improved mass transfer in fermentation.
- Increased fermentable sugars from beta glucan hydrolysis.

The benefits of the action of the xylanase in the production of starch and gluten fractions are:

- Higher gluten and starch yield due to efficient targeted degradation of the highly branched arabinoxylans of the cereal/grain fibre.
- More efficient removal of trapped water from the fibre, resulting in reduced evaporation load, leading to energy savings.
- Smoother operations and increased plant capacity.

The benefits, which are described above, are not exclusively obtainable by means of enzyme treatment but can be achieved without the use of enzymes, or with a reduced use of enzymes,



through e.g. modified maybe more expensive or less environmentally friendly production processes or recipe changes.

## D.1 Regulatory impact information

### D.1.1 Costs and benefits of the application

The application is not likely to place costs or regulatory restrictions on industry or consumers. Inclusion of the xylanase enzyme in Schedule 18—Processing aids will provide the food and beverage industry with the opportunity to improve processing of grains in several processes under environmentally friendly and cost efficient production conditions. For the government, the burden is limited to necessary activities for a variation of Schedule 18—Processing aids.

### D.1.2 Impact on international trade

The application is not likely to cause impact on international trade.

## E Information to support the application

### E.1 Data requirements

No public health and safety issues related to the proposed change are foreseen. As outlined in sections 3.3.2 C, D, E, F, the xylanase is produced by submerged fermentation of a genetically modified *Bacillus licheniformis* strain.

The safety of the production organism and the enzyme product has been thoroughly assessed:

- The production organism has a long history of safe use as production strain for food-grade enzyme preparations and is known not to produce any toxic metabolites.
- The genetic modifications in the production organism are well-characterised and safe and the recombinant DNA is stably integrated into the production organism and unlikely to pose a safety concern.
- The enzyme preparation complies with international specifications ensuring absence of contamination by toxic substances or noxious microorganisms
- Sequence homology assessment to known allergens and toxins shows that oral intake of the xylanase does not pose food allergenic or toxic concern.
- Two mutagenicity studies showed no evidence of genotoxic potential of the enzyme preparation.
- An oral gavage administration study in rats for 13-weeks showed that all dose levels were generally well tolerated and no evidence of toxicity.

## F Assessment procedure

Because the application is for a new source organism for an existing enzyme in the Code, it is considered appropriate that the assessment procedure is characterised as “General Procedure, Level 1”.

## G Confidential commercial information (CCI)

Detailed information on the raw materials used in production of the enzyme preparation and construction and characteristics of the genetically modified production strain are provided in **Appendix 4** and **6**, respectively. Summaries of the information are given in section A.4 and 3.3.2 E. The formal request for treatment of selected parts of **Appendix 4** and **6** as confidential commercial information (CCI) is included as **Appendix 1.1**.

## H Other confidential information

Apart from the selected parts of **Appendix 4** and **6** identified as confidential commercial information (CCI), no other information is requested to be treated as confidential.

## I Exclusive capturable commercial benefit (ECCB)

This application is not expected to confer an Exclusive Capturable Commercial Benefit.

## J International and other national standards

### J.1 International Standards

Use of enzymes as processing aids for food production is not restricted by any Codex Alimentarius Commission (Codex) Standards.

### J.2 Other national standards or regulations

With few exceptions on national, commodity standards, use of enzymes as processing aids for food production is in general not restricted by standards or regulations in other countries.

## K Statutory declaration

The Statutory Declaration is provided as a separate document together with this submission.

## L Checklist

This application concerns an enzyme product intended to be used as a processing aid. Therefore, the relevant documentation according to the Application Handbook from Food Standards Australia New Zealand as of 1 July 2019, are the following sections:

- Section 3.1.1 – General requirements
- Section 3.3.2 – Processing aids, subsections A, C, D, E, F

Accordingly, the checklist for General requirements as well as the Processing aids part of the checklist for applications for substances added to food was used and is included as **Appendix 1.2** and **1.3**.

## Chapter 3.3, Guidelines for applications for substances added to food

### 3.3.2 Processing Aids

The xylanase enzyme preparation described in this application is representative of the commercial food enzyme product for which approval is sought.

### A Technical information on the processing aid

#### A.1 Information on the type of processing aid

The xylanase enzyme preparation belongs to the category of processing aids described in Schedule 18—Processing aids.

The xylanase enzyme preparation is to be used in the food industry as a processing aid during the processing of raw materials containing xylan. Xylanases hydrolyse xylosidic linkages in xylans, including arbinoxylan present in grains for the production of several products, e.g., gluten, starch, potable alcohol, beer, and fats and oils.

The xylanase enzyme preparation is used in the following food manufacturing processes:

- distilled alcohol production
- the production of starch and gluten fractions

The highest dosage of the xylanase during a food manufacturing process is in processing of grains and potable alcohol production, where dosages up to 200 FXU(TB) per raw material (e.g., starch and cereals) are used.

#### A.2 Information on the identity of the processing aid

##### A.2.1 Enzyme

Generic name	xylanase
IUBMC nomenclature	endo-1,4- $\beta$ -xylanase
IUBMC No.	EC 3.2.1.8
Cas No.	9025-57-4

##### A.2.2 Enzyme preparation

The enzyme concentrate is formulated into a final enzyme preparation. The enzyme concentrate may be intended for a single enzyme preparation or a blend with other food enzymes and formulated as a liquid product depending on the characteristics of the intended food process in which it will be used.

The typical composition of the enzyme concentrate is:

Enzyme solids (TOS) <sup>1</sup>	approx. 2.1 %
Sorbitol	approx. 45.0 %
Sodium benzoate	approx. 0.45 %
Potassium sorbate	approx. 0.45 %
Water	approx. 52.0 %

The enzyme concentrate is standardised in xylanase units to an activity of 83 FXU(TB)/g. The Novozymes method used to determine the FXU(TB) activity is enclosed in **Appendix 3.2**.

### A.2.3 Host organism

The production strain was developed from the *Bacillus licheniformis* Si3 cell lineage, which was derived from the natural isolate *Bacillus licheniformis* Ca63. The Si3 cell lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously evaluated and regulatory approved food enzymes. The taxonomic classification of the recipient strain is:

Phylum	Firmicutes
Class	Bacilli
Order	Bacillales
Family	Bacillaceae
Genus	<i>Bacillus</i>
Species	<i>Bacillus licheniformis</i>

For a more detailed description of the host organism and the genetic modifications, please see section 3.3.2 E.

### A.2.4 Donor organism

The donor for the xylanase gene is as follows.

Phylum	Bacteroidota
Class	Flavobacteriia
Order	Flavobacteriales
Family	Weeksellaceae
Genus	<i>Chryseobacterium</i>
Species	<i>Chryseobacterium cucumeris</i> ( <i>Chryseobacterium</i> sp-10696)

---

<sup>1</sup> TOS = Total Organic Solids, defined as: 100 % - water - ash - diluents

The xylanase enzyme protein has been protein-engineered. For a more detailed description of the donor and the donor gene, please see section 3.3.2 E and **Appendix 6**.

### A.3 Information on the chemical and physical properties of the processing aid

The enzyme is an endo-1,4- $\beta$ -xylanase (EC 3.2.1.8), commonly known as xylanase. Endo-1,4- $\beta$ -xylanase catalyses the hydrolysis of (1 $\rightarrow$ 4)- $\beta$ -D-xylosidic linkages in xylans.

The enzyme preparation is available as liquid product. The appearance of the enzyme product is given in **Appendix 2.1**. The micro-organisms used for fermentation will consume the majority of the raw materials. Subsequent down-stream processes, such as washing and filtration steps will remove remaining amounts of raw material. Thus, the final food enzyme product will not contain significant residual amounts of the nutrients used for fermentation. This is confirmed by regular spot-testing, where analytical measurements show no detectable amounts of the allergens listed in **Appendix 2.1**.

The endo-1,4- $\beta$ -xylanase is active at temperatures up to 60 °C (with an optimum of 42 °C at pH 4) and within a pH range of 2 to 9 (an optimum of pH 5 at 37 °C). The temperature stability of the endo-1,4- $\beta$ -xylanase was determined at pH 4 and 30 min incubation showing that the enzyme retained almost full activity up to 38 °C, and that only negligible activity remained at 60 °C and above. The food processes, in which the enzyme is applied, include processing steps where it is denatured at high temperatures.

The food enzyme object of the present application is not added to final foodstuffs but used as a processing aid during food manufacturing. The enzyme exerts no function in the final food. In the final food the enzyme protein is either denatured by high temperature, which means that it does not have any action or any function, and is thus, like any other protein, inert; and/or removed in certain processing steps.

No reaction products, which could not be considered normal constituents of the diet, are formed during the production or storage of the enzyme-treated food.

### A.4 Manufacturing process

The manufacturing process comprises a fermentation process, a purification process, a formulation process and finally a quality control of the finished product, as outlined by Aunstrup (1979). This section describes the processes used in manufacturing of the xylanase enzyme product.

The enzyme preparation is manufactured in accordance with current Good Manufacturing Practices (**Appendix 4.1**). The quality management system used in the manufacturing process complies with ISO 9001:2015 (**Appendix 4.2**).

The raw materials are of food-grade quality and have been subjected to appropriate analysis to ensure their conformity with the specifications.

#### A.4.1 Fermentation

The xylanase is produced by submerged fed-batch pure culture fermentation of the genetically modified strain of *Bacillus licheniformis*, described in section 3.3.2 E.

#### A.4.1.1 Raw materials for fermentation

The production strain is grown in a medium consisting of compounds providing an adequate supply of carbon and nitrogen as well as minerals and vitamins necessary for growth. Furthermore, acids and bases for the adjustment of the pH and processing aids (e.g. antifoaming agents) are used during fermentation. The choice of raw materials used in the fermentation process (the feed, the seed fermenter, the main fermenter and dosing) is given in the confidential parts of **Appendix 4.3**.

#### A.4.1.2 Hygienic precautions

All equipment is designed and constructed to prevent contamination by foreign microorganisms.

All valves and connections not in use for the fermentation are sealed by steam at more than 120 °C.

After sterilization a positive pressure of more than 0.2 atmosphere is maintained in the fermentation tank.

The air used for aeration is sterilised by passing through a sterile filter. The inside of each fermentation tank is cleaned between fermentations by means of a high-pressure water jet and inspected after the cleaning procedures have been completed.

#### A.4.1.3 Preparation of the inoculum

The inoculum flask containing the prepared medium is autoclaved and checked. Only approved flasks are used for inoculation.

The stock culture suspension is injected aseptically into the inoculum flask and spread onto the medium in the flask. Once growth has taken place in the inoculum flask (typically after a few days at 30°C), the following operations are performed:

- Strain identity and traceability: ampoule number is registered
- Microbial purity: a sample from the inoculum flask is controlled microscopically for absence of microbial contaminants.

When sufficient amount of biomass is obtained and when the microbiological analyses are approved, the inoculum flask can be used for inoculating the seed fermenter.

#### A.4.1.4 The seed fermentation

The raw materials for the fermentation medium are mixed with water in a mixing tank. The medium is transferred to the seed fermenter and heat sterilised (e.g. 120 °C/60 min).

The seed fermentation tank is inoculated by transferring aseptically a suspension of cells from the inoculum flask.

The seed fermentation is run aerobically (sterile airflow), under agitation. The overpressure is kept above 0.2 atmosphere at all times, to prevent contamination.

Once a sufficient amount of biomass has developed, microbiological analyses are performed to ensure absence of contamination. The seed fermentation can then be transferred to the main fermentation tank.

#### A.4.1.5 The main fermentation

The raw materials for the medium are mixed with water in a mixing tank. The medium is transferred to the main fermenter and heat sterilised (e.g. 120 °C/60 min). If necessary, the pH is adjusted after sterilization, with sterile pH adjustment solutions.

The fermentation in the main tank is run as normal submerged fed-batch fermentation.

The main fermentation is run aerobically (sterile airflow), under vigorous agitation. The overpressure is kept above 0.2 atmosphere at all times, to prevent contamination. The fermentation is run at a well-defined temperature.

Fresh medium is added aseptically when the pH increases above its set point, and the dissolved oxygen concentration rises. The feed rate is adjusted so that there is no accumulation of carbohydrates.

Other parameters are measured at regular intervals

- refractive index
- enzyme productivity
- residual glucose
- residual ammonia

Samples are also taken at regular intervals to check absence of microbial contamination.

#### **A.4.2 Recovery**

The recovery process is a multi-step operation designed to separate the enzyme from the microbial biomass and partially purify, concentrate, and stabilize the food enzyme.

The steps of this process involve a series of typical unit operations:

- pre-treatment
- primary separation
- filtration
- concentration
- evaporation
- preservation and stabilization

##### A.4.2.1 Raw materials for recovery

The choice of raw materials used during recovery is given in the confidential parts of **Appendix 4.3**.

##### A.4.2.2 Pre-treatment

To facilitate the separation, flocculants are used in a pH-controlled process.

#### A.4.2.3 Primary separation

The cell mass and other solids are separated from the broth by well-established techniques such as pre-coat vacuum drum filtration or centrifugation.

The primary separation is performed at well-defined pH and temperature range.

#### A.4.2.4 Filtration

For removal of residual cells of the production strain and as a general precaution against microbial degradation, filtration on dedicated germ filtration media is applied. Pre-filtration is included when needed.

The filtrations are performed at well-defined pH and temperature intervals, and result in an enzyme concentrate solution free of the production strain and insoluble substrate components from the fermentation.

#### A.4.2.5 Concentration

Ultrafiltration and/or evaporation are applied for concentration and further purification. The ultrafiltration is applied to fractionate high molecular weight components (enzymes) from low molecular weight components and is used to increase the activity/dry matter ratio. Evaporation is used to increase the activity while maintaining the activity/dry matter ratio.

The pH and temperature are controlled during the concentration step, which is performed until the desired activity and activity/dry matter ratio has been obtained.

#### A.4.2.6 Evaporation

Evaporation is performed to remove water and increase the refractive index. The concentration is run at 0-45 °C and the refractive index is controlled during the concentration step to ensure that the dry matter content is within a given range.

#### A.4.2.7 Preservation and stabilization

For enzymatic, physical and microbial stabilization polyols as well as potassium sorbate and sodium benzoate are added to the enzyme concentrate.

#### A.4.2.8 Process control

Apart from the process controls performed during the various fermentation steps and described above, the following microbial controls are also performed.

Samples are withdrawn from both the seed fermenter and the main fermenter:

- before inoculation
- at regular interval during cultivation
- before transfer/harvest

The samples during all steps are examined by:

- microscopy
- plating culture broth on a nutrient agar and incubating for 24-48 hours



Growth characteristics are observed macroscopically and microscopically.

During the microbiological control steps, the number of foreign microorganisms should be insignificant. The fermentation parameters, *i.e.* enzyme activity, temperature and oxygen as well as pH are also monitored closely. A deviation from the normal course of the fermentation may signal a contamination.

If a significant contamination develops, the fermentation is terminated. The fermentation is regarded as “significantly contaminated” if two independent samples show presence of contaminating organisms after growth on nutrient agar.

Any contaminated fermentation is rejected for enzyme preparations to be used in a food-grade application.

## A.5 Specification for identity and purity

The xylanase enzyme product complies with the purity criteria recommended for Enzyme Preparations in Food, Food Chemicals Codex, 11th edition, 2018.

In addition to this, the xylanase enzyme product also conforms to the General Specifications for Enzyme Preparations Used in Food Processing as proposed by the Joint FAO/WHO Expert Committee on Food Additives in Compendium of Food Additive Specifications.

Analytical data for three representative, unstandardised batches of the xylanase enzyme preparation are shown in (Table 1). These data show compliance with the purity criteria of the specification.

**Table 1.** Analytical data for three representative enzyme product batches

Control parameter	Unit	Specification	Batch 1	Batch 2	Batch 3
xylanase activity	FXU(TB)/g		472	541	383
Lead	mg/kg	≤ 2	ND (LOD < 0.5)	ND (LOD < 0.5)	ND (LOD < 0.5)
Arsenic	mg/kg	≤ 1	ND (LOD < 0.3)	ND (LOD < 0.3)	ND (LOD < 0.3)
Cadmium	mg/kg	≤ 1	ND (LOD < 0.05)	ND (LOD < 0.05)	ND (LOD < 0.05)
Mercury	mg/kg	≤ 1	ND (LOD < 0.05)	ND (LOD < 0.05)	ND (LOD < 0.05)
Total viable count	CFU/g		<100	<100	<100
Total coliforms	CFU/g	≤ 30	<4	<4	<4
Enteropathogenic <i>Escherichia coli</i>	CFU/25 g	ND	ND	ND	ND
<i>Salmonella</i> spp.	CFU/25 g	ND	ND	ND	ND
Antimicrobial activity	—	ND	ND	ND	ND
Production strain	CFU/g	ND	ND	ND	ND

ND: not detected; LOD: limit of detection ; CFU: colony forming unit

A certificate of analysis of the presented data is attached as **Appendix 3.1**. The methods of analysis used to determine compliance with the specifications are enclosed (**Appendix 3**).

The xylanase enzyme preparation is available as a liquid enzyme product. The concentrate is standardised in xylanase units (FXU(TB)/g; **Appendix 3.2**). The preparation does not contain known food allergens (**Appendix 2.1** and **Appendix 4.3**).

## **A.6 Analytical method for detection**

The xylanase enzyme preparation is to be used in the food industry as a processing aid. This information is not required in the case of an enzymatic processing aid.

## **B Information related to the safety of a chemical processing aid**

Not applicable – this application does not concern a chemical processing aid.

## **C Information related to the safety of an enzyme processing aid**

### **C.1 General information on the use of the enzyme as a food processing aid in other countries**

The enzyme is used as processing aid during processing of xylan-containing raw materials in a range of countries, where there are no restrictions of the use of enzyme processing aids or where the enzyme is covered by a country positive list or specific approval.

The safety of the xylanase preparation has been evaluated and confirmed by external expert groups, as follows:

- Denmark: The enzyme preparation was safety assessed resulting in the authorisation of the enzyme product by the Danish Veterinary and Food Administration.
- France: The enzyme preparation was evaluated and approved by the competent authorities in France (Sous-direction de la sécurité sanitaire des aliments, Bureau des établissements et produits des industries alimentaires spécialisées).

### **C.2 Information on the potential toxicity of the enzyme processing aid**

#### **(a) Information on the enzyme's prior history of human consumption and/or its similarity to proteins with a history of safe human consumption**

A wide variety of enzymes are used in food processing. Enzymes, including xylanase, have a long history of use in food (Pariza and Foster, 1983; Pariza and Johnson, 2001).

In principle, xylanases can be used in the processing of all food raw materials, which naturally contain the substrates. Since the 1980s, xylanases have been used extensively in various industrial food applications such as grain and starch processing, manufacturing of alcohol, brewing and baking products (Beg et al., 2001). Xylanase enzyme preparations from various sources are widely authorised in, e.g. Australia and New Zealand, Brazil, Canada, China, Denmark, France, Japan, Mexico.

**(b) Information on any significant similarity between the amino acid sequence of the enzyme and that of known protein toxins**

A sequence homology assessment of the xylanase enzyme to known toxins was conducted. The amino acid sequence of the xylanase provided in **Appendix 6.4** was used as input for the search. No structural homologies to known toxins were found. The complete search report is enclosed in **Appendix 5.1**.

Furthermore, safety studies as described below were performed on a representative batch (PPQ69045) that was produced according to the description given in section 3.3.2 A.4, omitting stabilization and standardization. As a result, batch (PPQ69045 represents the enzyme concentrate and not the final enzyme product.

The following studies were performed:

- Ames Test. Test for mutagenic activity (**Appendix 5.2**)
- *In vivo* micronucleus test (**Appendix 5.3**)
- Toxicity study by oral gavage administration to rats for 13 weeks (**Appendix 5.4**)

The main conclusions of the safety studies can be summarised as follows:

- Xylanase PPQ69045 did not induce gene mutations in bacteria either in the presence or absence of metabolic activation (S-9) when tested under the conditions employed in this study.
- Xylanase, batch PPQ69045, is non-mutagenic at and up to 2000 mg TOS/kg body weight/day when the micronucleus test was conducted to determine the mutagenic potential of the batch using bone marrow cells from Swiss Albino mice.
- Oral gavage administration of Xylanase PPQ69045 to rats at doses up to 100 % of the tox test batch (962 mg TOS/kg bw/day for 13 weeks was well-tolerated and did not cause any adverse change. The NOAEL was considered to be 100 % of the tox test batch (equivalent to 962 mg TOS/kg bw/day).

Based on the presented toxicity data it can be concluded that the xylanase enzyme preparation, represented by batch PPQ69045, exhibits no toxicological effects under the experimental conditions described.

### **C.3 Information on the potential allergenicity of the enzyme processing aid**

**(a) Information of the source of the enzyme processing aid**

The xylanase enzyme is produced by an *Bacillus licheniformis* microorganism expressing the xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium* sp-10696). *Bacillus licheniformis* is ubiquitous in the environment and in general considered as a non-pathogenic fungus (see Section 3.3.2 D).

**(b) Analysis of similarity between the amino acid sequence of the enzyme and that of known allergens**

Enzymes have a long history of safe use in food, with no indication of adverse effects or reactions. Moreover, a wide variety of enzyme classes (and structures) are naturally present in food.

The allergenicity potential of enzymes was studied by Bindslev-Jensen et al. (2006) and reported in the publication: “Investigation on possible allergenicity of 19 different commercial enzymes used in the food industry”. The investigation comprised enzymes produced by wild-type and genetically modified strains as well as wild-type enzymes and protein engineered variants and comprised 400 patients with a diagnosed allergy to inhalation allergens, food allergens, bee or wasp. It was concluded from this study that ingestion of food enzymes in general is not likely to be a concern with regard to food allergy.

Additionally, food enzymes are used in small amounts during food processing resulting in very small amounts of the enzyme protein in the final food. A high concentration generally equals a higher risk of sensitization, whereas a low level in the final food equals a lower risk (Goodman et al., 2008).

A sequence homology assessment of the xylanase enzyme to known allergens was conducted (**Appendix 5.1**). The amino acid sequence of the xylanase provided in **Appendix 6.4** was used as input for the search. The xylanase was compared to allergens from the COMprehensive Protein Allergen REsource (COMPARE: <https://comparedatabase.org>).

Using higher than 35% identity in a sliding window of 80 amino acids as the criterion, a match was found for Phl p 4, a Berberine bridge enzyme from timothy grass (*Phleum pratense*). Phl p 4 is not reported as a food allergen but is known as a respiratory, occupational allergen. No homology to other allergens was found.

There is compelling evidence that persons affected by occupational asthma can ingest the respiratory allergen without acquiring clinical symptoms of food allergy, suggesting that inhalation is not likely to result in food allergy.

On the basis of the available evidence, it is concluded that oral intake of the xylanase is not anticipated to pose any food allergenic concern.

**C.4 Safety assessment reports prepared by international agencies or other national government agencies, if available**

Documentation of approval of the xylanase in Denmark is enclosed in **Appendix 2**.

## D Additional information related to the safety of an enzyme processing aid derived from a microorganism

### D.1 Information on the source microorganism

The xylanase enzyme is produced by a *Bacillus licheniformis* microorganism expressing the xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium* sp-10696). The *Bacillus licheniformis* host strain Si3 was developed from the natural isolate *Bacillus licheniformis* Ca63. The Si3 strain lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously evaluated and regulatory approved food enzymes.

The xylanase production strain is a non-pathogenic, non-toxicogenic, genetically modified *Bacillus licheniformis* strain. The production strain is marker-free, and it does not produce secondary metabolites of toxicological concern to humans as explained in Section E 1.3, Section A.5 and **Appendix 6.1**.

### D.2 Information on the pathogenicity and toxicity of the source microorganism

Industrial strains belonging to the *Bacillus licheniformis* species have a long history of safe use in food enzyme manufacturing (OECD, 1986). They have been used for decades in the production of enzymes, and in more than a decade as recombinant organisms for the production of a variety of bio-industrial products like food grade enzymes, vitamins, antibiotics, and additives (Schallmey et al., 2004).

The industrial production of alpha-amylase from *Bacillus licheniformis* was introduced in 1973 (Madsen et al., 1973). Since then, the bacterium has been safely used as a source of food enzymes such as carbohydrase (alpha-amylase) and protease for the production of various types of foods and food ingredients.

The Scientific Committee of EFSA has proposed to include a number of *Bacillus* species, including *Bacillus licheniformis*, on the list of QPS (Qualified Presumption of Safety) microorganisms due to the substantial body of knowledge available about these bacteria. Since all bacteria within the listed species potentially possess toxigenic traits, absence of toxigenic activity (emetic food poisoning toxins with surfactant activity and enterotoxigenic activity) must be verified (EFSA, 2007).

The Food and Drug Administration has affirmed that mixed carbohydrase and protease enzyme products derived from *Bacillus licheniformis* are generally recognized as safe (GRAS) in the production of certain foods including nutritive sweeteners, see 21CFR §184.1027 (Food and Drug Administration (FDA), 1983). In the supplementary information to the final rule in the Federal Register, FDA emphasized that “Published scientific literature as well as standard books on food microbiology demonstrate that *B. licheniformis* is widely recognized as a common contaminant found in many foods. None of these references report any toxicity or pathogenicity associated with the presence of this organism in food.”

In addition, the FDA did not question the conclusion that various other food enzymes obtained from genetically modified *Bacillus licheniformis* strains are GRAS under the intended conditions of use (GRN no. 22, 24, 72, 79, 265, 277, 472, 564, 572, 587, 594, 645, 689, 728, and 774).

JECFA has evaluated food enzymes derived from *Bacillus licheniformis*, including a genetically modified strain, and concluded that these food enzymes do not constitute a toxicological hazard (JECFA, 1987; JECFA, 2003).

The non-pathogenicity and non-toxigenicity of *Bacillus licheniformis* are thus strongly supported by the historic record of this organism.

The genetically modified *Bacillus licheniformis* host strain, used for production of the enzyme product, has been developed in a line of strains which have been used for production at Novozymes for many years and has an extensive history of commercial safe use for production of recombinant enzymes for food. It has been constructed using only well-characterized genetic material from class 1 microorganisms. No genetic material that can give rise to resistance towards antibiotics was left in the recipient strain as a result of the genetic modifications.

### D.3 Information on the genetic stability of the source organism

The inserted recombinant DNA is genetically stable during fermentation, as the inserted DNA is integrated into the chromosome.

Stability of the introduced DNA sequences was analysed using phenotypic characteristics of the production strain, *i.e.* enzyme activity and protein synthesis (**Appendix 6.5**).

For a more detailed description of the strain construction and characteristics, please see section 3.3.2 E.

## E Additional information related to the safety of an enzyme processing aid derived from a genetically-modified microorganism

### E.1 Information on the methods used in the genetic modification of the source organism

This section contains summarised information on the modifications of the host strain, on the content and nature of the introduced DNA and on the construction of the final production strain, as well as the stability of the inserted gene. The detailed information is provided in the confidential **Appendix 6**.

#### E.1.1 Host organism

The production strain was developed from the *Bacillus licheniformis* Si3 cell lineage, which was derived from the natural isolate *Bacillus licheniformis* Ca63. The Si3 cell lineage has a long history of safe use at Novozymes for production of food enzymes and has given rise to a number of food enzyme production strains, which are used for production of previously



evaluated and regulatory approved food enzymes. The taxonomic classification of the recipient strain is:

Phylum	Firmicutes
Class	Bacilli
Order	Bacillales
Family	Bacillaceae
Genus	<i>Bacillus</i>
Species	<i>Bacillus licheniformis</i>

The recipient strain used in the construction of the *Bacillus licheniformis* production strain, was derived from the parental strain through a combination of classical mutagenesis/selection and GM-steps. These steps were carried out in order to simplify purification, enhance product stability and increase the safety of the strain.

#### E.1.2 Introduced DNA

The vector used to transform the *Bacillus licheniformis* recipient strain are based on *Staphylococcus aureus* standard vectors (Gryczan et al., 1978; Horinouchi and Weisblum, 1982). No elements of the vector are left in the production strain. The xylanase expression cassette consisting of a hybrid *Bacillus* promoter, the coding sequence for xylanase from *Chryseobacterium cucumeris* (*Chryseobacterium* sp-10696) and a *Bacillus* terminator. The inserted xylanase gene was provided as a synthetic gene. Furthermore, the other vectors were used to remove marker genes in the recipient strain.

#### E.1.3 Construction of the recombinant microorganism

The *Bacillus licheniformis* production strain was constructed from the recipient strain through the following steps:

1. The xylanase expression cassette was integrated at specific integration sites present in the recipient strain.
2. A transformant was screened for rapid growth and high xylanase activity leading to the final production strain.

#### E.1.4 Antibiotic resistance gene

No functional antibiotic resistance genes were left in the strain as a result of the genetic modifications. Further details can be found in **Appendix 6.1**

#### E.1.5 Stability of the introduced genetic sequences

The transforming DNA is stably integrated into the *Bacillus licheniformis* chromosome and, as such, is poorly mobilised for genetic transfer to other organisms and is mitotically stable. Stability of the introduced DNA sequence was analysed using phenotypic characteristics of the production strain, i.e. enzyme activity and protein synthesis. Further details can be found in **Appendix 6.5**.

## **F Information related to the dietary exposure to the processing aid**

### **F.1 A list of foods or food groups likely to contain the processing aid or its metabolites**

The xylanase preparation is used as a processing aid during the manufacture of xylan-based products. Generally, xylanases hydrolyse xylosidic linkages in xylans, including arabinoxylan present in grains for the production of several products, e.g. gluten, starch, potable alcohol, beer, and fats and oils.

### **F.2 The levels of residues of the processing aid or its metabolites for each food or food group**

The xylanase enzyme preparation is used in the following food manufacturing processes:

- distilled alcohol production
- the production of starch and gluten fractions

#### **Use level**

The enzyme preparation is used at minimum levels necessary to achieve the desired effect and according to requirements for normal production following GMP.

The conditions of use of the xylanase preparation during food processing do not only depend on the type of application, but also on the food production process of each individual food manufacturer. In order to ensure optimal effectiveness of the enzyme at an acceptable economic cost the dosage, reaction time, process conditions and processing steps are adjusted.

The highest dosage given for solid food is 200 FXU(TB) per kg cereal (or cereal-derived) dry matter. This corresponds to 2.41 g of xylanase enzyme preparation per kg cereal (or cereal-derived) dry matter equivalent to 50.6 mg TOS per kg cereal (or cereal-derived) dry matter.

The highest dosage given for liquids is 200 FXU(TB) per kg starch (or starch-derived) dry matter. This corresponds to 2.41 g of xylanase enzyme preparation per kg starch (or starch-derived) dry matter equivalent to 50.6 mg TOS per kg starch (or starch-derived) dry matter.

#### **Enzyme residues in the final food**

The xylanase enzyme preparation is used as a processing aid during processing of grains and potable alcohol production. The enzyme is denatured by heat during processing and subsequently removed by repeated washing (processing of grain) and distillation (potable alcohol production). As a result, the presence of residual amounts of enzyme TOS is negligible.

F.2.1 Estimates of human consumption.



#### Method used for the dietary exposure assessment

An exposure assessment according to the Budget Method (Douglass et al., 1997; Hansen, 1966; ILSI, 1997) has been performed, as the processed xylan is used as an ingredient in a variety of food products and beverages.

#### *Budget Method*

Overall, the human exposure to the xylanase will be negligible because the enzyme preparation is used as a processing aid and in low dosages.

The Budget Method assumptions represent a “maximum worst case” situation of human consumption, in which the food enzyme object of the present application would be used at its maximum recommended dosages in all processed food and all processed beverages and not only in those food and drink processes described in Section F.2.

It is also supposed that the totality of the food enzyme will end up in the final food. This assumption is exaggerated since the enzyme protein and the other substances resulting from the fermentation are diluted or removed in certain processing steps.

As an example, distilled beverage spirits will neither contain any TOS (Total Organic Solids) originating from the food enzyme preparation nor from the fermentation mash due to the distillation step(s).

Therefore the safety margin calculation derived from this method is highly conservative.

#### *Assumptions in the Budget Method*

Solids	The maximum energy intake over the course of a lifetime is 50 kcal/kg body weight/day.
	50 kcal corresponds to 25 g foods.
	Therefore, adults ingest 25 g foods per kg body weight per day.
	Assuming that 50 % of the food is processed food, the daily consumption will be 12.5 g processed foods per kg body weight.
	It is further assumed that, in average, all processed food contains 25 % cereal (or cereal-derived) dry matter = 3.12 g cereal (or cereal-derived) dry matter per kg body weight per day.
Liquids	The maximum intake of liquids (other than milk) is 100 ml/kg body weight/day.
	Assuming that 25 % of the non-milk beverages is processed, the daily consumption will be 25 ml processed beverages per kg body weight.
	It is further assumed that all processed beverages contain 12 % starch (or starch-derived) dry matter = 3.0 g starch (or starch-derived) dry matter per kg body weight per day.
	It is assumed that the densities of the beverages are ~ 1.

#### TMDI (Total amount of dietary intake) calculation

##### *Solid food*

The highest dosage given for solid food is 200 FXU(TB) per kg cereal (or cereal-derived) dry matter, corresponding to 50.6 mg TOS per kg cereal (or cereal-derived) dry matter (cf. Section 3.3.2 A.2.2).

Based on this, 3.12 g cereal (or cereal-derived) dry matter in solid food will maximally contain:  
 $50.6 \text{ mg TOS per kg} / 1000 \text{ g per kg} \times 3.12 \text{ g} = 0.158 \text{ mg TOS}$

##### *Liquids*

The highest dosage given for liquids is 200 FXU(TB) per kg starch (or starch-derived) dry matter, corresponding to 50.6 mg TOS per kg starch (or starch-derived) dry matter (cf. Section 3.3.2 A.2.2).

Based on this, 3.0 g starch (or starch-derived) dry matter in liquids will maximally contain:  
 $50.6 \text{ mg TOS per kg} / 1000 \text{ g per kg} \times 3.0 \text{ g} = 0.152 \text{ mg TOS}$

##### *Total TMDI of xylan (or xylan-derived) solid foods and liquids*

$0.158 \text{ mg TOS} + 0.152 \text{ mg TOS} = 0.310 \text{ mg TOS}$

#### **F.2.2. Safety Margin Calculation**

The safety margin is calculated as dose level with no adverse effect (NOAEL) divided by the estimated human consumption (TMDI). The NOAEL dose level in the 13 weeks oral toxicity study in rats was concluded to be 962 mg TOS/kg bw/day (cf. Section 3.3.2 C 2).

The estimated human consumption is 0.310 mg TOS/kg/day

The safety margin can thus be calculated to be  $962/0.310 \approx 3103$ .

#### **F.3 For foods or food groups not currently listed in the most recent Australian or New Zealand National Nutrition Surveys (NNSs), information on the likely level of consumption**

Not relevant.

#### **F.4 The percentage of the food group in which the processing aid is likely to be found or the percentage of the market likely to use the processing aid**

It is assumed that all raw materials containing xylan are processed using the xylanase object of this submission as a processing aid at the highest recommended dosage.

#### **F.5 Information relating to the levels of residues in foods in other countries**

As described in F.2.1 above, a “worst case” calculation is made assuming that all organic matter originating from the enzyme is retained in the processed food product. The dietary

exposure is estimated using the Budget Method, as the processed xylan are used as an ingredient in a variety of food products.

**F.6 For foods where consumption has changed in recent years, information on likely current food consumption**

No significant changes in recent years are observed.

## List of references

- Aunstrup K (1979) Production, isolation, and economics of extracellular enzymes. In: *Applied Biochemistry and Bioengineering*. Elsevier, pp. 27–69.
- Beg, Q. K., Kapoor, M., Mahajan, L., & Hoondal, G. S. (2001). Microbial xylanases and their industrial applications: A review. *Applied Microbiology and Biotechnology*, 56(3–4), 326–338. <https://doi.org/10.1007/S002530100704>.
- Bindslev-Jensen C, Skov PS, Roggen EL, Hvass P and Brinch DS (2006) Investigation on possible allergenicity of 19 different commercial enzymes used in the food industry. *Food and Chemical Toxicology* 44(11). Elsevier: 1909–1915.
- Douglass JS, Barraj LM, Tennant DR, Long WR and Chaisson CF (1997) Evaluation of the budget method for screening food additive intakes. *Food Additives & Contaminants* 14(8). Taylor & Francis: 791–802.
- EFSA (2007) Introduction of a Qualified Presumption of Safety (QPS) approach for assessment of selected microorganisms referred to EFSA-Opinion of the Scientific Committee. *EFSA Journal* 5(12). Wiley Online Library: 587.
- Food and Drug Administration (FDA) (1983) Direct Food Substances Affirmed as GRAS, Mixed Carbohydrase and Protease Enzyme Product. 21 CFR Part 184. *Federal Register* 51(75): 13293.
- Goodman RE, Vieths S, Sampson HA, Hill D, Ebisawa M, Taylor SL and Van Ree R (2008) Allergenicity assessment of genetically modified crops—what makes sense? *Nature biotechnology* 26(1). Nature Publishing Group: 73–81.
- Gryczan TJ, Contente S and Dubnau D (1978) Characterization of *Staphylococcus aureus* plasmids introduced by transformation into *Bacillus subtilis*. *Journal of Bacteriology* 134(1). Am Soc Microbiol: 318–329.
- Hansen SC (1966) Acceptable daily intake of food additives and ceiling on levels of use. *Food and cosmetics toxicology* 4. Elsevier: 427–432.
- Horinouchi S and Weisblum B (1982) Nucleotide sequence and functional map of pE194, a plasmid that specifies inducible resistance to macrolide, lincosamide, and streptogramin type B antibiotics. *Journal of Bacteriology* 150(2). Am Soc Microbiol: 804–814.
- ILSI (1997) An evaluation of the budget method for screening food additive intake. Summary report of an ILSI Europe food chemical intake task force. ILSI Europe, Brussels, Belgium.
- JECFA (1987) *Carbohydrase (alpha-amylase) from Bacillus licheniformis*. World Health Organization. Available at: <https://apps.who.int/food-additives-contaminants-jecfa-database/chemical.aspx?chemID=1957>.
- JECFA (2003) Alpha-amylase (thermostable) from *Bacillus licheniformis* containing a modified alpha-amylase gene from *B. licheniformis*. World Health Organization. Available at: <https://apps.who.int/food-additives-contaminants-jecfa-database/chemical.aspx?chemID=4382>.

Madsen GB, Norman BE and Slott S (1973) A new, heat stable bacterial amylase and its use in high temperature liquefaction. *Starch-Stärke* 25(9). Wiley Online Library: 304–308.

OECD (1986) *Recombinant DNA Safety Considerations: Safety Considerations for Industrial, Agricultural, and Environmental Applications of Organisms Derived by Recombinant DNA Techniques*. Organization for Economic Co-operation; Development.

Pariza MW and Foster EM (1983) Determining the safety of enzymes used in food processing. *Journal of Food Protection* 46(5). International Association for Food Protection: 453–468.

Pariza MW and Johnson EA (2001) Evaluating the safety of microbial enzyme preparations used in food processing: Update for a new century. *Regulatory Toxicology and Pharmacology* 33(2). Elsevier: 173–186.

Schallmeyer M, Singh A and Ward OP (2004) Developments in the use of *Bacillus* species for industrial production. *Canadian journal of microbiology* 50(1). NRC Research Press Ottawa, Canada: 1–17.

## List of appendices

Appendices listed in **red, bold** font should be treated as confidential commercial information.

Appendix 1.1 Formal request for treatment of confidential commercial information (CCI)

Appendix 1.2 Checklist for general requirements

Appendix 1.3 Checklist for applications for substances added to food

Appendix 2.1 Product data sheet

Appendix 2.2 Danish approval document

Appendix 3.1 Certificate of analysis

Appendix 3.2 Method to determine Xylanase activity

Appendix 3.3 Method to determine heavy metals

Appendix 3.4 Method to determine total viable count

Appendix 3.5 Method to determine total coliforms

Appendix 3.6 Method to determine *Escherichia coli*

Appendix 3.7 Method to determine *Salmonella* spp.

Appendix 3.8 Method to determine antimicrobial activity

Appendix 4.1 GMP statement

Appendix 4.2 ISO certificate

### **Appendix 4.3 CCI Raw materials used during fermentation and recovery**

Appendix 4.3 non-CCI Raw Materials used during fermentation and recovery

Appendix 5.1 Sequence homology assessment

Appendix 5.2 Ames test report

Appendix 5.3 *In vivo* micronucleus study

Appendix 5.4 Toxicity study by oral gavage administration to rats for 13 weeks

### **Appendix 6 CCI Documentation regarding the production strain**

Appendix 6 non-CCI Documentation regarding the production strain